Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study

[1]  Y. Matsuda,et al.  Predictors of Responses to Corticosteroids for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study. , 2016, Journal of pain and symptom management.

[2]  E. Bruera,et al.  Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study , 2015, Cancer.

[3]  P. Fayers,et al.  Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Shaw,et al.  Corticosteroid prescribing in palliative care settings: a retrospective analysis in New Zealand , 2014, BMC Palliative Care.

[5]  Eduardo Bruera,et al.  Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Liying Zhang,et al.  Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. , 2013, Journal of pain and symptom management.

[7]  S. Iwase,et al.  Physician-reported corticosteroid therapy practices in certified palliative care units in Japan: a nationwide survey. , 2012, Journal of palliative medicine.

[8]  A. Abernethy,et al.  An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. , 2012, Journal of palliative medicine.

[9]  S. Iwase,et al.  Efficacy and undesirable effects of corticosteroid therapy experienced by palliative care specialists in Japan: a nationwide survey. , 2011, Journal of palliative medicine.

[10]  C. Earle,et al.  Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Selby,et al.  A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. , 2010, Journal of pain and symptom management.

[12]  A. Abernethy,et al.  Can we predict which patients with refractory dyspnea will respond to opioids? , 2007, Journal of palliative medicine.

[13]  T. Furukawa,et al.  Associated and predictive factors of sleep disturbance in advanced cancer patients , 2007, Psycho-oncology.

[14]  C. Fürst,et al.  The use of corticosteroids in Swedish palliative care , 2006, Acta oncologica.

[15]  I. Higginson,et al.  A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. , 2006, Journal of pain and symptom management.

[16]  M. Miyashita,et al.  Reliability and validity of the Japanese version of the Support Team Assessment Schedule (STAS-J) , 2004, Palliative and Supportive Care.

[17]  E. Bruera,et al.  Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. , 2004, Journal of pain and symptom management.

[18]  T. Nakano,et al.  Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Cleeland,et al.  Japanese version of the MD Anderson Symptom Inventory: a validation study. , 2003, Journal of pain and symptom management.

[20]  K. Muro,et al.  Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan , 2003, Supportive Care in Cancer.

[21]  F. Fulfaro,et al.  The use of corticosteroids in home palliative care , 2001, Supportive Care in Cancer.

[22]  P. Stone,et al.  A prospective survey of the use of dexamethasone on a palliative care unit , 2001, Palliative medicine.

[23]  T. Morita,et al.  Contributing factors to physical symptoms in terminally-ill cancer patients. , 1999, Journal of pain and symptom management.

[24]  T. Morita,et al.  Validity of the palliative performance scale from a survival perspective. , 1999, Journal of pain and symptom management.

[25]  A. Daley,et al.  Steroids in advanced cancer: survey of current practice. , 1992, BMJ.

[26]  T. Popiela,et al.  Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. , 1989, European journal of cancer & clinical oncology.

[27]  A. Pellegrini,et al.  Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. , 1989, European journal of cancer & clinical oncology.

[28]  E. Bruera,et al.  Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. , 1985, Cancer treatment reports.

[29]  K. Calman,et al.  Prednisolone as an appetite stimulant in patients with cancer. , 1984, British medical journal.

[30]  R. Hahn,et al.  Corticosteroid therapy of preterminal gastrointestinal cancer , 1974, Cancer.